Name (Synonyms) | Correlation | |
---|---|---|
drug1238 | Intervention App Wiki | 1.00 |
drug1822 | Placebo Wiki | 0.06 |
Name (Synonyms) | Correlation | |
---|---|---|
D001523 | Mental Disorders NIH | 0.21 |
D013313 | Stress Disorders, Post-Traumatic NIH | 0.20 |
D004194 | Disease NIH | 0.18 |
D001008 | Anxiety Disorders NIH | 0.17 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
This is a randomised, double-blind, placebo-controlled phase 2 trial investigating the safety and efficacy of C21 in subjects who are hospitalised with COVID-19 infection, but not in need of mechanical invasive or non-invasive ventilation. In total, approximately 100 subjects will be enrolled and randomised to receive twice daily oral administration of either standard of care (SoC) + placebo (N=50) or SoC + C21 (N=50). Subjects will be treated for 7 days.
Description: Primary endpoint
Measure: Change from baseline in C-reactive protein (CRP) after treatment with C21 200 mg daily dose (100 mg b.i.d.) Time: Treatment period of 7 days